HemaQuest Pharmaceuticals, Inc. Series B $12M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Antiviral, X - EBV, X - HIV, X - HPV, X - Hemoglobin, X - Sickle Cell, XX - MA

HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

Apr

2010

Genticel, S.A.: Series C $17.7M

Posted in I - Series C, Q - 1Q10, R - INTERNATIONAL, X - HPV, X - Oncology, X - THx, X - Vaccines

Genticel (France) a clinical-stage biopharmaceutical company focused on therapeutic vaccines for the prevention of cervical cancer in HPV infected women, closed a $17.7M Series C financing. Participants include AGF Private Equity, Institut Régional de Développement Industriel, Amundi Private Equity Funds, InnoBio Fund and Edmond de Rothschild Investment Partners.

Jun

2009

Lumavita, AG: Series A $5.5M

Posted in I - Series A, Q - 2Q09, R - INTERNATIONAL, X - HPV, X - HSV, X - Vaginitis

Lumavita (Switzerland) a clinical-stage biopharmaceutical company focused on anti-infectives for women’s health including vaginitis, HPV and HSV, closed a $5.5 Series A bring the total round up to $22M. Participants include HealthCap and Endeavour Vision.

Jun

2009

VaxInnate Corp., Series D $30M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Dengue, X - HPV, X - RSV, X - Vaccines, XX - NJ

VaxInnate (Cranbury, NJ) a clinical-stage vaccine company focused on infectious disease including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus, closed a $30M Series D financing. Participants include Wellcome Trust, New Leaf Venture Partners, Canaan Partners, HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures and CHL Medical Partners.

to top of page...